Top Page
Sonic Healthcare Limited
(Sydney:SHL)
Sonic Healthcare Limited (SHL) vs. iShares MSCI Australia ETF (EWA)
Sonic Healthcare Limited Business Overview & Revenue Model
Sonic Healthcare Limited Earnings Call Summary
Sonic Healthcare Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.65B | 9.65B | 8.93B | 8.14B | 9.31B | 8.75B |
| Gross Profit | 3.19B | 3.19B | 2.33B | 6.87B | 3.41B | 7.14B |
| EBITDA | 1.24B | 1.24B | 1.66B | 1.72B | 2.83B | 2.56B |
| Net Income | 513.60M | 513.60M | 511.09M | 684.98M | 1.46B | 1.32B |
Balance Sheet | ||||||
| Total Assets | 16.05B | 16.05B | 14.83B | 13.56B | 13.11B | 12.27B |
| Cash, Cash Equivalents and Short-Term Investments | 673.77M | 673.77M | 645.00M | 797.99M | 780.00M | 899.83M |
| Total Debt | 5.17B | 5.17B | 4.52B | 3.10B | 3.01B | 3.23B |
| Total Liabilities | 7.58B | 7.58B | 6.75B | 5.64B | 5.68B | 5.77B |
| Stockholders Equity | 8.32B | 8.32B | 7.92B | 7.74B | 7.27B | 6.38B |
Cash Flow | ||||||
| Free Cash Flow | 960.55M | 960.55M | 492.01M | 974.02M | 1.85B | 1.68B |
| Operating Cash Flow | 1.30B | 1.30B | 1.07B | 1.47B | 2.23B | 2.04B |
| Investing Cash Flow | -577.62M | -577.62M | -1.81B | -580.04M | -989.18M | -386.75M |
| Financing Cash Flow | -735.93M | -735.93M | 592.41M | -911.51M | -1.35B | -1.95B |
Sonic Healthcare Limited Technical Analysis
Sonic Healthcare Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$520.92M | 15.80 | 18.59% | 4.60% | 6.73% | 37.16% | |
67 Neutral | AU$292.23M | 11.68 | 10.25% | 6.22% | 6.65% | ― | |
64 Neutral | AU$11.07B | 20.94 | 6.32% | 4.69% | 9.44% | -0.37% | |
55 Neutral | AU$947.23M | 167.11 | 0.94% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €707.98M | -1.35 | -67.21% | ― | -23.02% | 33.11% | |
41 Neutral | AU$53.38M | -2.60 | -36.16% | ― | 62.81% | 16.37% |
Sonic Healthcare Limited Corporate Events
Sonic Healthcare Limited announced a change in the director’s interest, with James Pacey Newcombe acquiring 345,342 unlisted options and 50,481 unlisted performance rights over ordinary shares. These securities will vest in 2028, contingent on performance criteria, as part of the company’s long-term incentive plan approved at the 2025 AGM. This move reflects the company’s strategy to align executive compensation with performance, potentially impacting its operational focus and stakeholder interests by incentivizing leadership to meet long-term goals.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest notice, specifically concerning Christopher David Wilks. The notice details changes in the number of ordinary shares and unlisted options held directly and indirectly by the director, reflecting adjustments in the company’s stock and options management. This update is significant for stakeholders as it highlights the company’s ongoing commitment to transparency in its corporate governance practices.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced the issuance of 111,971 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize its employees, potentially enhancing workforce motivation and aligning employee interests with company performance, thereby strengthening its market position.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced the issuance of 730,792 unquoted equity securities under an employee incentive scheme. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced the cessation of Colin Stephen Goldschmidt as a director, effective November 20, 2025. The notice details Goldschmidt’s interests in various securities, including ordinary shares, unlisted options, and performance rights, which are part of the company’s employee option and performance rights plans. This transition may impact the company’s governance structure and could have implications for its strategic direction and stakeholder relations.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, specifically regarding Colin Stephen Goldschmidt’s holdings. The notice details the number of shares and options held by the director, including various unlisted options and performance rights with specific vesting periods and exercise prices. This change in director’s interest could impact the company’s governance and potentially influence investor perceptions.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced the appointment of James Pacey Newcombe as a director, effective November 20, 2025. As part of his role, Newcombe holds various unlisted options over ordinary shares in the company, which are part of the Sonic Healthcare Limited Employee Option Plan. This appointment and the associated options indicate a strategic move to align the interests of the director with the long-term goals of the company, potentially impacting its governance and operational strategies.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced the cessation of 4,546,633 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited held its 2025 Annual General Meeting as a hybrid event, where all proposed resolutions were approved by shareholders through a poll. This outcome reflects strong shareholder support and may positively impact the company’s governance and strategic direction, reinforcing its position in the healthcare industry.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced at its 2025 Annual General Meeting that Dr. Colin Goldschmidt will retire as CEO, with Dr. Jim Newcombe taking over the role. The company also confirmed its earnings guidance for the fiscal year 2026, indicating stability and continuity in its financial performance. This leadership transition and reaffirmation of financial targets suggest a steady strategic direction for the company, potentially reassuring investors and stakeholders about its future prospects.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.80 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a significant leadership transition as Dr. Colin Goldschmidt retires, with Dr. Jim Newcombe stepping in as the new Managing Director and CEO. Under Goldschmidt’s leadership, Sonic expanded globally and became the third largest pathology player worldwide. The company reported strong financial performance for 2025, with revenue reaching A$9.6 billion and a net profit of A$514 million, and anticipates continued growth in 2026. The appointment of Evangelos Kotsopoulos as COO and the addition of Nicola Wakefield Evans to the Board highlight Sonic’s focus on strengthening its executive team and board diversity. Sonic also emphasized its ongoing commitment to sustainability and corporate responsibility, with progress in assessing climate-related risks and human rights management.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.80 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has released its 2025 Sustainability Report, which is available online for shareholders who opted for electronic communication. This report highlights Sonic’s ongoing commitment to sustainability, which could enhance its operational efficiency and strengthen its position in the healthcare industry.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.80 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, with Director Nicola Wakefield Evans acquiring an additional 2,500 fully paid ordinary shares, bringing her total to 6,500 shares. This acquisition reflects confidence in the company’s future performance and may positively influence stakeholder perceptions of the company’s stability and growth prospects.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.80 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced its 2025 Annual General Meeting, scheduled for November 20, 2025, to be held as a hybrid meeting. The company will not send physical copies of the Notice of Meeting unless specifically requested by shareholders, and the 2025 Annual Report is available online. This move reflects a shift towards digital communication, potentially enhancing shareholder engagement and operational efficiency.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.80 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, with Director Katharine Giles acquiring an additional 1,000 fully paid ordinary shares, bringing her total to 5,600 shares. This on-market purchase reflects a continued investment in the company, potentially indicating confidence in Sonic Healthcare’s future performance and stability, which may reassure stakeholders and investors.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.80 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced a change in the director’s interest, with Katharine Giles acquiring an additional 1,000 fully paid ordinary shares in the company, bringing her total to 4,600 shares. This on-market purchase reflects a continued confidence in the company’s performance and may influence stakeholder perceptions positively, indicating potential growth and stability within the company.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced a change in the director’s interest, specifically involving Mark Raymond Compton. On October 2, 2025, Compton acquired 1,500 fully paid ordinary shares in Sonic Healthcare Limited through an on-market purchase, increasing his indirect holdings in the company. This change reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Sonic Healthcare’s future performance and stability.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited has announced a change in the shareholding interests of its director, Christine Bennett. On October 1, 2025, Bennett acquired an additional 1,100 fully paid ordinary shares in the company through an on-market purchase, bringing her total holdings to 8,200 shares. This acquisition reflects a continued confidence in the company’s performance and future prospects, potentially impacting stakeholders’ perception of the company’s stability and growth trajectory.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, specifically regarding Christopher David Wilks. The notice outlines the direct and indirect interests in the company’s securities, including ordinary shares and unlisted options. This change in director’s interest reflects ongoing adjustments in the company’s governance and may impact stakeholder perceptions regarding the company’s strategic direction and leadership stability.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, specifically regarding Colin Stephen Goldschmidt’s holdings. The update includes details of direct and indirect interests in ordinary shares and unlisted options, reflecting the company’s ongoing commitment to transparency in its governance. This change may impact stakeholders by providing insights into the director’s confidence in the company’s future performance and aligning executive interests with shareholder value.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, with Director Suzanne Crowe acquiring 2,365 fully paid ordinary shares through an on-market purchase. This change reflects an increase in indirect holdings, potentially indicating confidence in the company’s future performance and stability, which may positively influence stakeholder perception.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.
Sonic Healthcare Limited announced a change in the director’s interest, with Kathryn (Kate) Dianne Spargo acquiring an additional 3,500 fully paid ordinary shares through an on-market purchase. This change reflects a potential increase in confidence or strategic positioning by the director, which could impact the company’s governance and investor perceptions.
The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.